Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22262501 | 0.75 | XDH (0.49) | XDHSCN9AKDM4CPTGER1PIM1 | |
| SCHEMBL17850741 | 0.74 | XDH (0.56) | XDHSCN9AKDM4CPTGER1KMO | |
| SCHEMBL17835489 | 0.74 | KDM4C (0.43) | XDHSCN9AKDM4CPTGER1CYP11B2 | |
| SCHEMBL20476485 | 0.74 | ALDH1A1 (0.50) | XDHPTGER1CNR2DHFRDCPS | |
| SCHEMBL23022111 | 0.70 | KDM4E (0.45) | XDHSCN9AKDM4CPIM1PIM3 | |
| SCHEMBL20476411 | 0.69 | XDH (0.46) | XDHSCN9APTGER1 | |
| SCHEMBL22262263 | 0.68 | XDH (0.44) | XDHSCN9APTGER1PIM1PIM2 | |
| SCHEMBL31080672 | 0.67 | ATXN2 (0.41) | XDHPIM1CYP11B2PDE4DIRAK4 | |
| SCHEMBL23022110 | 0.67 | MELK (0.41) | XDHKDM4CPIM1PIM3PIM2 | |
| SCHEMBL840900 | 0.67 | XDH (0.54) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2019-02-14 | — | — | US | disclosed |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-11-20 | — | — | US | disclosed |
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-3233847-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex Suisse SA (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016098005-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034500-A1 | Amido thiazole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348296-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | XDH 9/4885SCN9A 1449/4885KDM4C 4494/4885 |
| US-20190046515-A1 | AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX5, CYBB | XDH 9/4885SCN9A 1449/4885KDM4C 4494/4885 |
| US-10130619-B2 | Amido thiadiazole derivatives as NADPH oxidase inhibitors | NOX1, NOX5, CYBB | XDH 9/4885SCN9A 1449/4885KDM4C 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.